Head-To-Head Review: Galectin Therapeutics (NASDAQ:GALT) versus Nanobiotix (NASDAQ:NBTX)

Galectin Therapeutics (NASDAQ:GALT) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Risk & Volatility

Galectin Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Profitability

This table compares Galectin Therapeutics and Nanobiotix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Nanobiotix	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Galectin Therapeutics and Nanobiotix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1	0	1	0	2.00
Nanobiotix	1	1	4	0	2.50

Galectin Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 368.09%. Nanobiotix has a consensus price target of $37.33, indicating a potential upside of 6.06%. Given Galectin Therapeutics’ higher possible upside, research analysts clearly believe Galectin Therapeutics is more favorable than Nanobiotix.

Insider and Institutional Ownership

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Galectin Therapeutics and Nanobiotix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84 million	($0.41)	-5.73
Nanobiotix	$36.87 million	46.32	-$27.11 million	N/A	N/A

Nanobiotix has higher revenue and earnings than Galectin Therapeutics.

Summary

Nanobiotix beats Galectin Therapeutics on 7 of the 9 factors compared between the two stocks.

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.